| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
219,000,000 |
| Market
Cap: |
19.02(B) |
| Last
Volume: |
1,303,852 |
Avg
Vol: |
1,735,384 |
| 52
Week Range: |
$55.17 - $86.96 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 235 |
| Guru Rank Value : 6.7 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
29,216 |
52,744 |
110,594 |
186,187 |
| Total Sell Value |
$2,029,428 |
$3,628,415 |
$7,790,720 |
$12,562,362 |
| Total People Sold |
4 |
5 |
5 |
6 |
| Total Sell Transactions |
12 |
18 |
26 |
39 |
| End Date |
2025-07-06 |
2025-04-04 |
2024-10-04 |
2023-10-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Heeson Lee |
EVP, Head of Incyte Intl |
• – – |
2025-10-01 |
4 |
D |
$86.70 |
$40,142 |
D/D |
(463) |
32,315 |
|
- |
|
| Mayes Patrick A |
EVP & Chief Scientific Officer |
• – – |
2025-10-01 |
4 |
D |
$86.70 |
$136,032 |
D/D |
(1,569) |
65,819 |
|
- |
|
| Harrigan Edmund |
Director |
– • – |
2025-09-30 |
4 |
A |
$84.81 |
$24,510 |
D/D |
289 |
20,608 |
|
- |
|
| Baker Julian |
|
– • • |
2025-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
776 |
28,187,969 |
|
- |
|
| Clancy Paul J |
Director |
– • – |
2025-09-30 |
4 |
A |
$84.81 |
$24,171 |
D/D |
285 |
23,235 |
|
- |
|
| Gardner David H |
EVP, Chief Strategy Officer |
• – – |
2025-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,429 |
9,429 |
|
- |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-09-16 |
4 |
S |
$83.15 |
$23,116 |
D/D |
(278) |
33,200 |
|
-3% |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-09-16 |
4 |
OE |
$64.25 |
$17,862 |
D/D |
278 |
33,478 |
|
- |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-09-02 |
4 |
S |
$84.97 |
$50,812 |
D/D |
(598) |
33,200 |
|
-0% |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-09-02 |
4 |
OE |
$58.06 |
$34,720 |
D/D |
598 |
33,798 |
|
- |
|
| Basi Ramitpal K |
EVP, Human Resources |
• – – |
2025-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
6,506 |
6,506 |
|
- |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-08-15 |
4 |
S |
$86.81 |
$24,046 |
D/D |
(277) |
33,200 |
|
1% |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-08-15 |
4 |
OE |
$64.25 |
$17,797 |
D/D |
277 |
33,477 |
|
- |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-08-04 |
4 |
S |
$75.77 |
$45,310 |
D/D |
(598) |
33,200 |
|
-11% |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-08-04 |
4 |
OE |
$58.06 |
$34,720 |
D/D |
598 |
33,798 |
|
- |
|
| Mayes Patrick A |
EVP & Chief Scientific Officer |
• – – |
2025-07-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
67,388 |
|
28% |
|
| Stein Steven H |
EVP & Chief Medical Officer |
• – – |
2025-07-21 |
4 |
S |
$67.94 |
$251,786 |
D/D |
(3,706) |
102,886 |
|
-28% |
|
| Flannelly Barry P |
EVP & General Manager US |
• – – |
2025-07-16 |
4 |
S |
$68.36 |
$91,602 |
D/D |
(1,340) |
35,149 |
|
-25% |
|
| Iyengar Vijay K |
EVP, GMAPPS |
• – – |
2025-07-16 |
4 |
S |
$68.36 |
$67,198 |
D/D |
(983) |
40,540 |
|
-25% |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-07-16 |
4 |
S |
$68.36 |
$53,663 |
D/D |
(785) |
33,200 |
|
-25% |
|
| Issa Mohamed Khairie |
EVP, Head of US Oncology |
• – – |
2025-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,769 |
85,252 |
|
- |
|
| Trotta Matteo |
EVP, GM, Dermatology US |
• – – |
2025-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,261 |
15,016 |
|
- |
|
| Trotta Matteo |
EVP, GM, Dermatology US |
• – – |
2025-07-15 |
4 |
D |
$68.25 |
$12,422 |
D/D |
(182) |
9,755 |
|
- |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,184 |
33,985 |
|
- |
|
| Denton Sheila A. |
EVP & General Counsel |
• – – |
2025-07-15 |
4 |
D |
$68.25 |
$47,980 |
D/D |
(703) |
25,801 |
|
- |
|
1081 Records found
|
|
Page 1 of 44 |
|
|
0.57 (0.66%) 
